前列腺动脉闭塞与前列腺动脉栓塞治疗良性前列腺增生的比较:犬模型早期结果
在17只成年雄性比格犬中比较Onyx-18行前列腺动脉闭塞(PAO,n=7)与微球行前列腺动脉栓塞(PAE,n=10)的技术效能与安全性。PAO组透视时间(23.80 vs 36.24 min,p=0.014)和辐射剂量(68.19 vs 125.26 mGy,p=0.003)显著低于PAE组;两组前列腺体积变化百分比在2周(30.71% vs 37.89%)和1个月(56.41% vs 55.56%)均无显著差异。PAO诱导的前列腺缺血范围在1周时显著大于PAE(43.44% vs 18.91%,p=0.001)。
要点
- 犬模型中PAO与PAE均双侧成功,技术可行且效能与安全性相当。
- PAO组透视时间及辐射剂量显著低于PAE组。
- PAO组1周前列腺缺血范围显著大于PAE组。
核心结论
- EVOH行PAO在技术上可行,效能与安全性与微球PAE相当,PAO可能较PAE有优势。
研究设计与样本
- 犬模型研究:17只成年雄性比格犬行PAO(n=7,Onyx-18)或PAE(n=10,300-500 µm微球),术前及术后1周、2周、1个月行MRI评估前列腺体积,随访1个月观察并发症,随访血管造影评估前列腺动脉再通。
关键影像表现/征象
- 两组手术均双侧成功。
- PAO组平均透视时间23.80 min vs PAE组36.24 min,p=0.014。
- PAO组平均辐射剂量68.19 mGy vs PAE组125.26 mGy,p=0.003。
- PAO组1周平均前列腺缺血范围43.44% vs PAE组18.91%,p=0.001。
- 两组前列腺体积变化百分比在2周(PAO 30.71% vs PAE 37.89%)和1个月(PAO 56.41% vs PAE 55.56%)无显著差异。
临床应用与阅片要点
- 原文结论认为EVOH行PAO技术可行,效能与安全性与微球PAE相当,PAO可能较PAE有优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the technical efficacy and safety between prostatic artery occlusion (PAO) with ethylene vinyl alcohol copolymer (EVOH) and prostatic artery embolizsation (PAE) with microspheres in a canine model.
METHODS: 17 adult male beagles underwent PAO (n = 7) with Onyx-18 or PAE (n = 10) with microspheres (300-500 µm). To evaluate the primary outcomes (technical efficacy and safety), MRI evaluations were performed immediately before and 1 week, 2 weeks, and 1 month after procedures to document prostate volume (PV); and all dogs were inspected for procedure-related complications during 1 month follow-up. The secondary outcomes included the prostate ischaemia size detected by MRI and recanalisation of prostatic artery by follow-up angiography. Differences between groups were statistically analysed.
RESULTS: Both procedures were bilaterally successful in all animals. Compared with PAE, the mean fluoroscopy time (23.80 vs 36.24 min, p = 0.014) and radiation dose (68.19 vs 125.26 mGy, p = 0.003) were significantly less in PAO procedure. The mean percentage of PV change significantly decreased in both groups at 2 weeks (30.71% vs 37.89%) and 1 month (56.41% %vs 55.56%) after PAO and PAE respectively), without significant differences between groups at either time point. No major complications were observed except one animal after PAO with transient haematuria and acute urinary retention. The mean prostate ischaemia induced by PAO was significant greater compared with PAE at 1 week (43.44% vs 18.91%, p=0.001). PAO with EVOH is technically feasible and with comparable efficacy and safety with PAE. There are possible benefits to PAO over PAE.
ADVANCES IN KNOWLEDGE: A new technical modification of the PAE consisting of the use of liquid embolic agent to occlude the prostatic artery trunk and its branches has been developed in pre-clinical study, showing to be an effective and safe procedure which can induce a significant prostate shrinkage for the management of symptomatic benign prostatic hyperplasia in patients. In addition, the findings have showed a similar therapeutic effect comparable with the conventional PAE using microspheres.
引用
- Lucas-Cava, Sánchez-Margallo, Dávila-Gómez, et al. Prostatic artery occlusion versus prostatic artery embolisation for the management of benign prostatic hyperplasia: early results in a canine model. Br J Radiol. 2022. PMID: 35762334. doi:10.1259/bjr.20220243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。